Event Type
Disclosure
Voluntary
Variant
8-K
and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193
Other Events. On November 8, 2025, positive results from a Phase 2 study of safusidenib in Japanese patients with chemotherapy- and radiotherapy-naïve grade 2 I
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Corporate Presentation of Nuvation Bio Inc. (November 17, 2025) 104 Cover Page I